Safety of combination therapy with milrinone and esmolol for heart protection during percutaneous coronary intervention in acute myocardial infarction
- 312 Downloads
Ischemia/reperfusion injury remains an untreated clinical problem in patients with acute myocardial infarction (AMI) despite significant advances in emergent revascularization through percutaneous coronary intervention (PCI). Pharmacological intervention for infarct size reduction is unavailable. We have identified that the medications milrinone and esmolol, when administered together at the beginning of the reperfusion, significantly decrease infarct size via reducing reperfusion injury in an experimental model. The present study tested the safety of combination therapy of milrinone and esmolol (M + E) in patients with AMI.
Sixteen subjects with AMI requiring PCI were consecutively recruited. M + E was intravenously infused simultaneously for 10 min started at 5 min before anticipated angioplasty balloon inflation. Another 16 consecutively recruited AMI patients requiring PCI served as a placebo arm treated per routine clinical protocol. Blood pressure (BP) and heart rate (HR) were monitored continuously during PCI.
M + E combination therapy resulted in a trend of non-significant reduction in BP compared with a control group. There was a modest but significant increase in HR at the later phase of M + E infusion compared with a control group. No significant cardiac arrhythmia was induced during M + E infusion.
The combination therapy with M + E produces a minimal change in hemodynamics and appears safe as an adjunctive therapy to PCI in AMI patients. Further studies are warranted.
Keywordsacute myocardial infarction esmolol milrinone reperfusion injury
This study was supported in part by the American Heart Association National Scientist Development Grant (to MH). We thank Dr. Barry Uretsky for his critical review and helpful comments on this work.
Conflict of interest
Drs. Ming-He Huang and Kenichi Fujise hold a patent (US8415384B2) related to this study.
- 4.Dzavik V, Sleeper LA, Picard MH, Sanborn TA, Lowe AM, Gin K et al (2005) Outcome of patients aged >75 years in the should we emergently revascularize occluded coronaries in cardiogenic shock (SHOCK) trial: do elderly patients with acute myocardial infarction complicated by cardiogenic shock respond differently to emergent revascularization? Am Heart J 149:1128–1134PubMedCrossRefGoogle Scholar
- 8.Huang MH, Nguyen V, Rastogi S, Wu Y, Birnbaum Y, Lin Y et al (2007) Post-ischemic therapy with calcitonin gene-related peptide and β2-adrenergic receptor agonist confers synergistic infarct size reduction. Circ Res (abstract)101:1210Google Scholar